Wells Fargo & Company MN decreased its position in shares of AstraZeneca plc (NYSE:AZN) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,301,237 shares of the company’s stock after selling 105,587 shares during the quarter. Wells Fargo & Company MN’s holdings in AstraZeneca were worth $149,253,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in AZN. Valeo Financial Advisors LLC bought a new position in AstraZeneca during the 3rd quarter worth approximately $133,000. Calton & Associates Inc. acquired a new stake in shares of AstraZeneca during the 4th quarter worth approximately $181,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $184,000. Neumann Capital Management LLC acquired a new stake in shares of AstraZeneca during the 4th quarter worth approximately $202,000. Finally, Clean Yield Group acquired a new stake in shares of AstraZeneca during the 4th quarter worth approximately $205,000. Hedge funds and other institutional investors own 14.91% of the company’s stock.
Several analysts have recently commented on the stock. BMO Capital Markets reaffirmed a “buy” rating and set a $38.00 price objective on shares of AstraZeneca in a research report on Friday, January 26th. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. ValuEngine upgraded AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Leerink Swann reiterated a “market perform” rating and set a $36.00 target price (up from $33.00) on shares of AstraZeneca in a research note on Thursday, January 18th. Finally, Sanford C. Bernstein lifted their target price on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $35.20.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.86. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The firm had revenue of $5.78 billion for the quarter, compared to analysts’ expectations of $5.49 billion. During the same period in the prior year, the business posted $1.21 earnings per share. The company’s revenue was up 3.4% on a year-over-year basis. sell-side analysts predict that AstraZeneca plc will post 1.67 EPS for the current year.
The business also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Stockholders of record on Friday, February 16th will be given a dividend of $0.95 per share. This represents a dividend yield of 5.62%. The ex-dividend date is Thursday, February 15th. AstraZeneca’s dividend payout ratio is presently 57.81%.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.